ArQule, Inc. Enrolls First Patient in Phase 1 Trial With ARQ 087, an FGFR Inhibitor

Published: Dec 13, 2012

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor) activity.

Back to news